Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19

• DOI: 10.1007/s40121-021-00477-9
• Publication Date: 2021-06-11T12:02:43Z
• Authors: Fernanda Meira; Estela Moreno-García; Laura Linares; Irene Macaya; Adria Tomé; Marta Hernández-M...; Laia Albiach; Laura Morata; Laura Letona; Marta Bodro; Alberto Cózar-Llistó; Celia Cardozo; Mariana Chumbita; Cristina Pitart; Juan Ambrosioni; Verónica Rico; Daiana Agüero; Pedro Puerta-Alcalde; Nicole Garcia-Pouton; Francesc Marco; Carolina Garcia-V...; Alex Soriano; José Antonio Mart...
• Keywords: Hydroxychloroquine

The study aim was to assess the influence of inflammatory response modifiers, including anti-interleukin-6 (IL-6) biologics and corticosteroids, on incidence hospital-acquired infections in patients with coronavirus disease 2019 (COVID-19). Case–control performed at a university hospital from February 26 May 26, 2020. Cases were defined as COVID-19 who developed infections. For each case, two controls selected among without matched obeying three criteria hierarchical sequence: length stay up until first infection; comorbidity; need for Intensive care unit (ICU) admission. Conditional logistic regression analysis used estimate association exposures being case. A total 71 cases 142 included. Independent predictors acquiring infection chronic liver [odds ratio (OR) 16.56, 95% CI 1.87–146.5, p = 0.012], morbid obesity (OR 6.11, 1.06–35.4, 0.043), current or past smoking 4.15, 1.45–11.88, 0.008), exposure hydroxychloroquine 0.2, 0.041–1, 0.053), invasive mechanical ventilation 61.5, 11.08–341, ≤ 0.0001). Inflammatory modifiers had no acquisition nosocomial admitted COVID-19. Hospital-acquired primarily occurred critically ill main conferring risk.